- |||||||||| Review, Journal: Ferroptosis defense mechanisms: The future and hope for treating osteosarcoma. (Pubmed Central) - Jun 26, 2024
In this paper, we summarize how, through the three major defense systems of ferroptosis, not only can substances from traditional Chinese medicine, antitumor drugs, and nano-drug carriers induce ferroptosis in OS cells, but they can also be combined with immunotherapy, differentiation therapy, and other treatment modalities to significantly enhance chemotherapy sensitivity and inhibit tumor growth. Thus, ferroptosis holds great potential in treating OS, offering more choices and possibilities for future clinical interventions.
- |||||||||| Review, Journal: The role of N?-terminal acetylation in protein conformation. (Pubmed Central) - Jun 26, 2024
In this review, we zoom in on one possible functional consequence of N?-terminal protein acetylation; its effect on protein folding. Using selected examples of proteins associated with human diseases such as alpha-synuclein and huntingtin, here, we discuss the sometimes contradictory findings of the effects of N?-terminal protein acetylation on protein (mis)folding and aggregation.
- |||||||||| Journal: A case of angiosarcoma of the scalp with cardiac tamponade and hemothorax. (Pubmed Central) - Jun 26, 2024
Using selected examples of proteins associated with human diseases such as alpha-synuclein and huntingtin, here, we discuss the sometimes contradictory findings of the effects of N?-terminal protein acetylation on protein (mis)folding and aggregation. No abstract available
- |||||||||| Journal: Residential proximity to oil and gas developments and childhood cancer survival. (Pubmed Central) - Jun 26, 2024
In neither case was HS truly present in this patient, but immunocytochemistry provided information that helped to optimize the patient's chemotherapy recommendations. Residential proximity to oil or gas wells at diagnosis is associated with the risk of mortality in children with AML or hepatoblastoma.
- |||||||||| Review, Journal: The role of O-GlcNAcylation in bone metabolic diseases. (Pubmed Central) - Jun 25, 2024
However, the potential mechanisms by which O-GlcNAcylation regulates bone metabolism are not fully understood. In this paper, the literature related to the regulation of bone metabolism by O-GlcNAcylation was summarized to provide new potential therapeutic strategies for the treatment of orthopedic diseases such as arthritis and osteoporosis.
- |||||||||| Journal: Dual targeting of KDM1A and antioxidants is an effective anticancer strategy. (Pubmed Central) - Jun 25, 2024
We also show that KDM1A-specific inhibitor bizine synergized with antioxidant-depleting therapies, buthionine sulfoximine, and auranofin in rhabdomyosarcoma cell lines (Rh28 and Rh30). In this study, we describe a novel role for KDM1A in regulating HIF- 1A functions under oxidative stress and found that dual targeting of KDM1A and antioxidant systems may serve as an effective combination anticancer strategy.
- |||||||||| Review, Journal: Advancements in osteosarcoma management: integrating immune microenvironment insights with immunotherapeutic strategies. (Pubmed Central) - Jun 25, 2024
Additionally, it underscores the imperative for subsequent research to further investigate the intricate interactions between the tumor microenvironment and the immune system, aiming to devise more effective treatment strategies. The present review comprehensively addresses the landscape of osteosarcoma immunotherapy, delineating crucial scientific concerns and clinical challenges, thereby outlining potential research directions.
- |||||||||| Review, Journal: Prevalence of childhood cancer survivors in Europe: a scoping review. (Pubmed Central) - Jun 25, 2024
The large variations in LDP and CP estimates were linked to differences in data availability, the selection of populations, prevalence measure, statistical method, incidence period, index date, age at diagnosis and prevalence, cancer types, sex, and, for LDP, also the length of follow-up. Standardisation of methodology and reporting are needed to systematically monitor and compare CCS prevalence in Europe and provide data to help address survivors' needs.
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), Imfinzi (durvalumab) / AstraZeneca, Yervoy (ipilimumab) / BMS
Trial completion date, Trial primary completion date, Combination therapy, Checkpoint inhibition, Metastases: Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors (clinicaltrials.gov) - Jun 25, 2024 P1/2, N=100, Recruiting, Not yet recruiting --> Recruiting Trial completion date: Oct 2025 --> Oct 2035 | Trial primary completion date: Oct 2024 --> Oct 2029
|